Learn peptides step by step

MOTS-c's 503A Recommendation: What Changed and What Did Not

MOTS-c now has a favorable advisory recommendation. It still does not have FDA drug approval or an open 503A compounding path.

SafetyIntermediate

Telehealth Peptide Prescribing After the 2026 PCAC Votes

A favorable advisory vote is not permission to prescribe or compound. Here is the practical standard telehealth clinics should use after the 2026 PCAC meeting.

August 14, 2026 Peptide Research Signals: What to Watch Next

The newest peptide research batch is less about hype and more about the questions each compound answers. Retatrutide, tesamorelin, BPC-157, GHK-Cu, and MOTS-C all point at different tracking priorities.

Retatrutide Progress Check: How to Tell If the Weight You're Losing Is the Right Kind

Scale weight can lie when appetite drops, water shifts, and training changes. This checklist shows the signals that matter more than a single number on the scale.

11m

Beginner Peptide Dosing for Adults: How People Choose a Conservative First Protocol

Mid-40s and new to peptides? This guide explains how beginners typically choose a conservative first protocol using goals, compound class, published ranges, and tracking — without inventing a prescription.

12m

Kisspeptin-10 Peptide Guide: What It Does, Fertility Research, and Common Misspellings (Kispeptin)

Kisspeptin-10 sits upstream of GnRH in reproductive endocrinology research. This guide explains mechanism, what people track, dosing as community discussion only, and why Kispeptin searches miss the mark.

12m

Retatrutide and Tesamorelin Together: What the Stack Question Really Means

Reta plus Tesa is one of the most asked stack questions in 2026. This guide explains why people combine metabolic and visceral-fat peptides, what to track, and why same-syringe mixing is usually avoided.

11m

Selank Reconstitution Guide: 10 mg Vial, BAC Water, and Dose Math (incl. "Sealink" Misspelling)

A 10 mg Selank vial looks simple until you mix the wrong diluent volume or chase a Sealink listing. This guide covers BAC reconstitution math, route context, and tracking habits — educational only, not medical advice.

August 2026 Peptide Research Roundup: What Changed for Retatrutide, BPC-157, MOTS-c, and GHK-Cu

The latest peptide research wave is less about hype and more about what survives real-world tracking. Here is the practical read on retatrutide, BPC-157, MOTS-c, and GHK-Cu.

Retatrutide in 2026: Why the Strongest Weight-Loss Signal Still Needs Body-Composition Tracking

Retatrutide is still the loudest metabolic signal in the room. The people who get the best result are the ones who track body composition, not just pounds lost.

August 2026 Peptide Research Snapshot: Recovery, GLP-1, Collagen, and Mitochondria

The clearest signal in today's peptide research is not one molecule. It is the pattern: recovery peptides, metabolic peptides, collagen support, and mitochondrial tools all need tighter tracking.

Cagrilintide Dosing Guide: Solo vs CagriSema 2.4 mg Weekly

Cagrilintide is the amylin half of CagriSema. Here's the dosing map people actually search — 2.4 mg weekly combo context, monotherapy signal, and how not to cross-titrate with eloralintide.

SafetyIntermediate

Eloralintide Side Effects: What Phase 2 Tolerability Data Suggests

Amylin agonists can feel GLP-1-like in the gut. Here's how to think about eloralintide tolerability, escalation, and symptom tracking without turning trial data into fear content.

MariTide vs Weekly GLP-1s: Monthly Conjugate vs Weekly Agonists

Weekly vs monthly is the real MariTide comparison. Here's how Amgen's conjugate stacks up conceptually against weekly dual/triple agonists — without fake head-to-heads.

Mazdutide Dosing Guide: 4 mg and 6 mg Weekly Protocols Explained

Mazdutide is a once-weekly glucagon/GLP-1 dual agonist with clear Phase 3 dose anchors at 4 mg and 6 mg. Here's the dosing and results map searchers want.

Tesamorelin and Waist-First Tracking: The Metrics That Matter Most

Tesamorelin is a body-composition tool, not a bathroom-scale trick. The best results show up when you track the right metrics from the start.

Retatrutide Weight-Loss Data: What the New Numbers Mean for Body Composition

Retatrutide is forcing a better conversation about fat loss. The scale matters, but body composition, protein, and strength tell you whether the result will hold.

Appetite Control on Peptides: What to Track Before the Scale Moves

Appetite control is useful only if it does not turn into under-eating. Track the right signals early so the scale does not hide the real tradeoffs.

BPC-157 Safety in 2026: What the Evidence Actually Says About Recovery and Risk

BPC-157 has a real research footprint, but most of the confidence in the compound still comes from preclinical work. That gap matters when people start talking about safety like the answer is settled.

FDA Peptide Compounding Review: What the Seven-Peptide Debate Means for Buyers and Clinics

Regulation does not settle the peptide debate by itself. It forces clearer questions about sourcing, safety, evidence, and who is responsible when claims move faster than data.

GLP-1s and Muscle Health: What the Latest Meta-Analysis Means for Body Recomposition

GLP-1 weight loss is not the same as automatic muscle loss. The real story depends on protein, resistance training, and tracking.

GLP-1 Muscle Preservation: How to Keep Lean Mass While Losing Fat in 2026

GLP-1s can drive impressive weight loss, but the real win is losing fat without giving up strength. This guide shows how to protect lean mass while appetite is down.

12m

InsightsIntermediate

PeptIQ H1 2026 Report: What Thousands of Real Peptide Logs Reveal

Retatrutide dominates H1 logging, the Wolverine stack is real, and quick-log onboarding predicts who actually tracks. Our first semi-annual data report from thousands of real peptide logs.

GLP-1s and Biological Aging: What the New Semaglutide Study Shows

GLP-1 research is moving into healthspan and epigenetic aging. The new semaglutide signal is worth tracking, but it is not proof of age reversal.

Amylin and GLP-1: The Next Wave of Metabolic Peptides

The next metabolic peptide wave is not just stronger GLP-1 dosing. Amylin, GIP, glucagon, and combination protocols are changing what serious tracking should include.

GLP-1s Before Bariatric Surgery: What the 2026 Evidence Says

GLP-1 peptides are changing the bariatric surgery conversation. The practical lesson is not self-managing around surgery. It is better tracking, clearer handoffs, and coordinated medical planning.

Dapiglutide: What the GLP-1/GLP-2 Obesity Trial Means

Dapiglutide is not another simple GLP-1 copycat. The early 2026 trial missed statistical significance for weight loss, but the mechanism points toward the next phase of peptide design.

GLP-1 Discontinuation: How to Maintain Weight Loss After Stopping

A 2025 Biomolecules review highlights the hardest GLP-1 question: what happens after the weight comes off? Maintenance needs a plan before the final dose.

GLP-1 Lean Mass Loss: What 2026 Data Shows

A new 2026 meta-analysis puts real numbers on lean mass change during semaglutide, tirzepatide, and liraglutide weight loss. The practical takeaway is not panic. It is better tracking.

GLP-1 Nutrition Strategy: Protein, Muscle, and Labs

New 2026 reviews show a nutrition gap in GLP-1 and incretin therapy research. Here is how to protect protein intake, lean mass, hydration, and labs while appetite is suppressed.

Start hereBeginner

Peptides for Women: What to Know Before You Start

Women have unique considerations with peptides, from hormones and cycle changes to muscle retention, recovery, skin health, and tracking.

Retatrutide Not Working for Weight Loss? Here's What to Check

You've been on Retatrutide for 4-6 weeks and the scale hasn't budged. Before you give up or double your dose, here are the real reasons Reta might not be 'working' — and what to actually do about it.

10m